peptid
precursor
compound
synthes
solid
phase
use
method
analog
previous
report
synthesi
analog
also
provid
us
first
opportun
synthes
test
nonsymmetr
nmethyl
pattern
eg
compound
previou
attempt
accomplish
use
onbead
olefin
crossmetathesi
met
modest
yield
best
cu
catalyz
huisgen
cycloaddit
conduct
resin
use
methodolog
describ
meldal
case
method
provid
desir
compound
follow
cleavag
resin
concomit
deprotect
singl
major
peak
analyt
hplc
previou
work
monitor
bindingdepend
quench
benzo
g
quinolin
fluoresc
determin
dissoci
unfortun
initi
attempt
measur
affin
triazolecontain
compound
fss
rna
fluoresc
titrat
unsuccess
due
irrevers
photobleach
compound
therefor
measur
bind
constant
surfac
plasmon
reson
spr
tabl
assay
rna
immobil
spr
chip
compound
flow
solut
allow
determin
kinet
rate
constant
bind
well
thermodynam
comparison
measur
affin
indic
substitut
triazol
olefin
effect
affin
within
error
nmethyl
modest
effect
affin
compound
display
highest
affin
bind
constant
tighter
previous
describ
nmethyl
amid
analog
affin
enhanc
larg
driven
increas
onrat
ka
consist
hypothesi
nmethyl
reduc
complex
ground
state
conform
ensembl
favor
conform
conform
abl
bind
rna
known
propens
nmethyl
alter
peptid
order
test
select
spr
measur
made
use
competit
assay
mixtur
compound
plu
excess
yeast
trna
rel
compound
concentr
solut
flow
spr
chip
cours
constitut
even
larger
excess
trna
amount
fss
rna
immobil
sensor
chip
repres
stringent
assay
observ
compound
test
show
signific
chang
kd
presenc
trna
cellular
permeabl
toxic
assess
cell
toxic
first
examin
via
triazolecontain
compound
significantli
less
toxic
previous
report
compound
figur
previou
data
shown
refer
compound
particular
essenti
nontox
highest
examin
concentr
although
previou
experi
produc
cluster
toxic
among
close
relat
analog
bind
fss
triazolecontain
compound
found
spread
toxic
differ
compound
particularli
unexpect
compound
chemic
similar
compound
toxic
dose
compound
found
roughli
twice
toxic
flow
cytometri
reveal
permeabl
triazol
analog
larg
follow
methyl
pattern
tetranmethyl
compound
display
greatest
cell
permeabl
nonnmethyl
compound
least
support
inform
result
consist
trend
previous
observ
compound
unmethyl
olefin
tetramethyl
olefin
provid
figur
refer
evalu
compound
select
examin
effect
concentr
compound
cell
rnaseq
total
transcript
analyz
condit
set
significantli
alter
gene
rel
control
compound
two
concentr
compar
use
web
tool
one
sampl
behav
outlier
therefor
analysi
conduct
without
consid
sampl
disregard
outlier
sampl
reveal
transcript
statist
signific
chang
compoundtr
condit
figur
two
show
greater
chang
consid
biolog
set
genbank
id
pseudogen
inclus
outlier
sampl
analysi
result
subset
transcript
call
differenti
express
therefor
although
priori
conclud
inclus
outlier
biolog
relev
exclus
produc
conserv
estim
compound
effect
cell
sampl
show
addit
transcript
signific
chang
includ
express
gene
earli
growth
respons
fold
chang
microtubul
associ
protein
light
chain
beta
fold
chang
phosphatidylinositol
type
beta
fold
chang
ubiquitin
specif
peptidas
fold
chang
test
concentr
lower
chang
metabol
indic
toxic
observ
vide
supra
compound
addit
chang
may
reflect
compounddepend
increas
cell
stress
examin
overal
howev
low
number
significantli
alter
transcript
particular
near
absenc
express
gene
alter
highlight
select
compound
despit
statu
leastselect
triazol
analog
studi
base
trna
competit
spr
next
examin
effect
triazolecontain
fss
rna
binder
pseudotyp
hiv
virion
product
infect
produc
cell
first
transfect
provir
hiv
plasmid
modifi
env
gene
delet
nef
gene
replac
green
fluoresc
protein
gfp
assist
virion
detect
quantit
cotransfect
vesicular
stomat
viru
type
g
vsvg
plasmid
provid
envelop
function
tran
enabl
product
singlecycl
infecti
virion
visual
gfp
product
fluoresc
microscopi
also
allow
qualit
assess
virion
product
produc
cell
virion
produc
incub
variou
concentr
compound
harvest
use
infect
tzmbl
report
cell
virion
quantiti
first
normal
via
elisa
assay
tzmbl
cell
express
luciferas
upon
infect
via
hiv
ltr
promot
provid
quantit
readout
infect
indinavir
fdaapprov
proteas
employ
posit
control
observ
compound
substanti
decreas
virion
product
concentr
depend
manner
evidenc
decreas
gfp
fluoresc
support
inform
virion
produc
less
infecti
infect
decreas
strongli
increas
concentr
compound
figur
new
compound
slightli
less
effect
previous
report
compound
offset
significantli
lower
toxic
western
blot
use
assess
effect
fssbind
compound
gaggagpol
ratio
use
antibodi
probe
new
compound
found
increas
amount
gagpol
rel
gag
strongest
effect
figur
also
examin
lysat
compoundtr
produc
cell
western
blot
signific
chang
gaggagpol
ratio
observ
rel
control
suggest
excess
gagpol
product
packag
virion
support
inform
confirm
activ
compound
replicationcompet
viru
examin
effect
compound
propag
hiviiib
common
laboratori
human
tcell
line
cell
first
infect
viru
h
absenc
compound
spun
resuspend
fresh
media
vari
concentr
compound
ad
condit
test
triplic
preliminari
experi
compound
onehalf
medium
harvest
day
postinfect
replac
equival
volum
medium
compound
medium
remov
examin
viral
particl
use
elisa
assay
procedur
repeat
day
postinfect
experi
reveal
dose
timedepend
inhibit
hiviiib
three
compound
support
inform
low
compound
undetect
compound
level
viru
present
highest
dose
day
postinfect
subsequ
full
profil
obtain
compound
day
postinfect
figur
valu
obtain
via
fourparamet
logist
fit
data
indic
similar
potenc
respect
somewhat
higher
potenc
compound
decreas
viru
due
inhibit
cell
growth
inde
cell
present
compoundtr
well
untreat
virusinfect
well
day
support
inform
measur
alamar
blue
assay
effect
strike
consist
compoundmedi
protect
virusinduc
apoptosi
effect
seen
antihiv
compound
prove
toxic
hivinfect
cell
concentr
fsstarget
compound
inhibit
via
differ
mechan
exist
antivir
also
examin
abil
inhibit
multidrugresist
strain
viru
patientderiv
strain
resist
broad
rang
proteas
inhibitor
nucleosid
revers
transcriptas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
also
highli
use
similar
protocol
employ
hiviiib
experi
detail
infect
human
cell
treat
dose
evalu
product
viru
elisa
cell
surviv
alamar
blue
day
postinfect
gratifi
observ
compound
inhibit
strain
provid
statist
signific
protect
cytopath
effect
figur
continu
need
develop
new
antihiv
therapi
particularli
explor
novel
therapeut
hiv
frameshift
recogn
time
attract
potenti
avenu
viral
inhibit
previous
lack
effect
strategi
sequenceselect
rna
recognit
made
address
target
challeng
past
work
demonstr
feasibl
degrad
infect
pseudotyp
hiv
via
fss
rnatarget
compound
demonstr
first
time
strategi
also
yield
compound
abl
strongli
inhibit
replic
laboratori
strain
hiv
human
cell
one
compound
inhibit
highli
cytopath
multidrugresist
strain
critic
step
valid
fss
rna
therapeut
target
also
import
note
frameshift
limit
wide
use
mani
pathogen
virus
exampl
sar
also
eukaryot
includ
recod
process
possibl
control
point
drive
therapeut
outcom
approach
appli
frameshift
extend
synthet
molecul
control
broad
rang
recod
event
broader
context
rna
recognit
work
also
demonstr
use
triazol
disulfid
bioisoster
effect
structur
depict
figur
minim
version
may
use
densiti
function
method
basi
set
van
der
waal
surfac
color
electrostat
potenti
visual
avogadro
compound
synthes
use
standard
solid
phase
peptid
protocol
wang
resin
mmolgram
alkyn
contain
monom
mmolgram
azid
contain
monom
activ
carbonyl
diimidazol
cdi
equiv
dimethylformamid
dmf
h
follow
treatment
equiv
dmf
h
amino
acid
coupl
use
equiv
aa
phe
pro
pra
aha
nmeph
equiv
hatu
equiv
dipea
dmf
h
deprotect
fmoc
accomplish
use
piperidin
dmf
h
nme
amino
acid
need
commerci
avail
fmoc
first
remov
use
standard
method
follow
treatment
resin
equiv
chlorid
nosylcl
equiv
collidin
dcm
h
activ
resin
treat
ml
tmsdiazomethan
ml
methanol
dcm
overnight
methyl
monitor
hplc
remov
nosyl
group
resin
treat
equiv
equiv
dbu
end
monom
cap
benzo
g
quinolin
form
substitut
triazol
ring
azidecontain
peptid
cleav
trifuoroacet
acid
tfa
triethyl
silan
te
water
ether
precipit
yield
crude
yellow
solid
use
without
purif
next
resinbound
alkyn
dri
vacuum
wash
three
time
dri
thf
cui
equiv
dipea
equiv
ad
vessel
anhydr
thf
mix
min
azid
equiv
base
resin
load
ad
result
greenbrown
solut
mix
overnight
resin
wash
three
time
thf
three
time
dcm
three
time
dmf
three
time
dcm
cleav
tfa
te
water
h
follow
rotari
evapor
ether
precipit
spr
conduct
use
biacor
x
biacor
inc
instrument
streptavidin
immobil
ru
flow
cell
use
edcnh
coupl
chip
ge
surfac
block
ethanolamin
next
fss
obtain
hplcpurifi
sampl
integr
dna
technolog
inc
refold
mm
hepe
mm
nacl
ph
heat
heater
block
min
cool
rt
immobil
one
flow
cell
spr
chip
densiti
ru
control
flow
cell
block
inject
biotin
mm
hepe
mm
nacl
ph
compound
inject
flow
rate
mm
hepe
mm
nacl
tween
ph
min
inject
repeat
twice
consist
trace
fit
individu
langmuir
model
cell
plate
cellswel
plate
dmem
fetal
bovin
serum
penicillinstreptomycin
cell
allow
adher
h
incub
compound
h
triplic
total
premix
clontech
ad
incub
h
follow
measur
use
perkinelm
enspir
plate
reader
line
provid
logist
fit
data
cell
grown
dmem
fetal
bovin
serum
confluenc
plate
treat
compound
h
cell
trypsin
pellet
wash
twice
dpb
gibco
cell
resuspend
ice
cold
dpb
incub
propidium
iodid
stain
dead
cell
total
event
collect
use
bd
lsrii
flow
cytomet
cell
plate
sixwel
plate
allow
grow
confluencey
million
cell
treat
h
triplic
cell
process
accord
valid
protocol
develop
univers
rochest
genom
research
center
analyz
rnaseq
illumina
sequenc
read
clean
accord
rigor
preprocess
workflow
map
human
refer
genom
gencod
version
human
gene
annot
use
perform
differenti
express
analysi
fals
discoveri
rate
fdr
cutoff
confid
interv
antivir
activ
rnatarget
compound
measur
singleround
infect
assay
pseudotyp
use
produc
cell
provir
vector
includ
gene
except
nef
replac
gfp
env
thu
preserv
gag
pol
frameshift
requir
product
gagpol
polyprotein
singleround
infect
assay
conduct
transient
transfect
viral
vector
vsvg
coat
protein
vector
ratio
use
fugen
hd
promega
viru
produc
cell
dose
compound
h
transfect
viral
particl
harvest
media
h
transfect
filter
syring
filter
viral
load
normal
elisa
perkinelm
infect
perform
use
tzmbl
report
cell
contain
stabli
integr
firefli
luciferas
express
driven
hivltr
promot
therefor
luciferas
express
upon
success
hiv
infect
triplic
infect
plate
cellswel
pg
proceed
h
addit
steadyglo
reagent
promega
well
min
luminesc
measur
quantit
metric
chang
viral
infect
presenc
compound
cell
obtain
nih
aid
reagent
program
grown
rpmi
media
supplement
fetal
bovin
serum
cell
seed
cell
cultur
flask
ml
infect
hiviiib
concentr
ng
infect
allow
proceed
h
humidifi
incub
cell
collect
centrifug
min
excess
viru
remov
cell
wash
dpb
cell
resuspend
fresh
growth
media
plate
cultur
dish
cellswel
compound
ad
cell
triplic
final
concentr
total
volum
brought
mlwell
day
postinfect
ml
supernat
collect
well
replac
ml
fresh
media
compound
correspond
concentr
given
day
postinfect
ml
supernat
collect
alamar
blue
cell
viabil
reagent
thermofish
ad
well
alamar
blue
fluoresc
measur
exem
nm
bandwidth
supernat
frozen
subsequ
analysi
viral
load
via
elisa
accord
manufactur
instruct
advanc
bioscienc
laboratori
alamar
blue
elisa
plate
read
mulitmod
detector
beckman
coulter
